The United States are known for being ahead of the pack when it comes to most things, but in particular, facial rejuvenation and plastic surgery.
Now, there’s a new product that’s just made its way through the US Food and Drug Administration (FDA) called Kybella.
According to a report on News.com.au, Kybella is made from deoxycholic acid, which is a chemical produced in the body to help absorb fats. Reportedly, once injected into the fat below the chin, known as submental fat, it works to destroy the fat cells.
The same report reveals that patients are able to receieve up to 50 injections in one single treatment, with up to six treatments administered no less than one month apart.
“I’ve never seen a demand like this, except for Botox,” Derek Jones, a dermatologist on the faculty at UCLA and lead investigator in the clinical FDA trials of Kybella, told the Hollywood Reporter. “We have a waiting list of people who have been calling for months.”
Apparently, the makers of Botox are aware of just how effective and valuable Kybella will be, with Allergan, the pharmaceutical company that owns Botox set to acquire Kythera Biopharmaceuticals this week for $2.1 billion.
It shouldn’t matter too much though, as professionals estimate Kybella will cost between $US500 and $US600 per treatment.
According to Kybella’s website, 79 per cent of patients treated with Kybella reported satisfaction with the appearance of their face and chin.
But be warned, as with any procedure, there are side effects, including swelling, bruising, pain, numbness, redness, difficulty swallowing and nerve injury in the jaw that causes facial muscle weakness.